摘要
目的探讨缬沙坦在慢性肺源性心脏病合并高血压心力衰竭治疗中的临床效果分析。方法选取我院2012年6月~2014年6月收治的慢性肺源性心脏病合并高血压心力衰竭患者95例,随机分为对照组和实验组。实验组给予缬沙坦进行治疗,对照组给予福辛普利治疗。治疗后,比较两组的血压、心功能、超声心动图指标及临床疗效。结果治疗后,两组的舒张压、收缩压均较治疗前显著降低（P〈0.05）,且实验组的改善程度显著优于对照组（P〈0.05）;治疗后,两组的纽约心脏病学会心功能分级、心电图ST段下移均较治疗前显著改善（P〈0.05）,且实验组的改善程度显著优于对照组（P〈0.05）;治疗后实验组左心室收缩末期内径、左心室射血分数及左心室舒张末期内径较治疗前显著改善,且改善程度显著优于对照组（P〈0.05）;实验组治疗总有效率显著高于对照组（P〈0.05）。结论缬沙坦治疗慢性肺源性心脏病合并高血压心力衰竭患者,能逆转左心室肥厚、改善心功能,具有良好的降压效果,临床效果显著,值得临床推广应用。
Objective To explore the clinical effect analysis of valsartan in chronic pulmonary heart disease combined with hypertension-induced heart failure. Methods From June 2012 to June 2014,95 patients with chronic pulmonary heart disease and hypertension-induced heart failure in our hospital were selected and randomly divided into control and experimental groups.In the experimental group,valsartan was used,while in the control group,fosinopril was applied.After treatment,the blood pressure,cardiac function,indexes of ultrasonic cardiogram,and clinical efficacy between two groups were compared. Results After therapy,the diastolic blood pressure and systolic blood pressure were both significantly decreased between two groups compared with that before treatment respectively（P0.05）,and improvement in experimental group was greatly better than that in control group respectively（P0.05）.The classification of cardiac function by New York Heart Association and ST segment depression by electrocardiogram between two groups was obviously improved compared with that before treatment respectively（P0.05）,these indexes in experimental group was superior to that in control group respectively（P0.05）.The left ventricular systolic diameter,left ventricular ejection fraction,and left ventricular end-diastolic diameter in experimental group was remarkably improved after treatment in comparison with that before treatment respectively,and improvement in experimental group was better than that in control group（P 0.05）.The total therapeutic effective rate in experimental group was much higher than that in control group（P0.05）.Conclusion In the treatment of patients with chronic pulmonary heart disease combined with hypertension-induced heart failure,valsartan can reverse left ventricular hypertrophy and improve cardiac function with a good antihypertensive effect.It is remarkable in clinical effect,and is worthy of application and promotion in clinic.
出处
《中国当代医药》
2015年第25期114-116,共3页
China Modern Medicine
关键词
缬沙坦
慢性肺源性心脏病
高血压心力衰竭
Valsartan
Chronic pulmonary heart disease
Hypertension-induced heart failure
